2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate
C93H149N3O46S3 — CID 157089729
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate
2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate (PubChem CID 157089729) has the molecular formula C93H149N3O46S3 and a molecular weight of 2141.39 g/mol. Its IUPAC name is 2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate.
Molecular Properties
| Compound Name | 2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate |
|---|---|
| PubChem CID | 157089729 |
| Molecular Formula | C93H149N3O46S3 |
| Molecular Weight | 2141.39 g/mol |
| Exact Mass | 2139.86 |
| IUPAC Name | 2-[[(1S,3R,6S,8S,11S,13R,16S,18R,21S,23R,26S,28S,31S,33R,36R,38R,40R,42R,44R,46R,48R)-30-(2-carboxybutylsulfanylmethyl)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-5,15,20,25,35-pentakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methylsulfanylmethyl]-4-oxo-6-[2-(3-oxobutoxy)ethoxy]hexanoic acid;[(4S,7R,8S,9S,10Z,13Z,16S)-8-hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-2,6-dioxo-1-azacyclohexadeca-10,13-dien-4-yl] 6-aminohexanoate |
| SMILES | C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)NC(=O)C[C@H](OC(=O)CCCCCN)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C1.CCC(CSCC1O[C@@H]2O[C@@H]3C(CO)O[C@H](O[C@@H]4C(CO)O[C@H](O[C@@H]5C(CO)O[C@H](O[C@@H]6C(CSCC(CC(=O)CCOCCOCCC(C)=O)C(=O)O)O[C@H](O[C@@H]7C(CO)O[C@H](O[C@@H]8C(CO)O[C@H](O[C@H]1[C@H](O)C2O)C(O)[C@H]8O)C(O)[C@H]7O)C(O)[C@H]6O)C(O)[C@H]5O)C(O)[C@H]4O)C(O)[C@H]3O)C(=O)O |
| InChI | InChI=1S/C60H98O41S2.C33H51N3O5S/c1-3-21(52(82)83)16-102-18-29-50-36(73)43(80)59(93-29)98-48-27(14-64)89-55(39(76)32(48)69)95-45-24(11-61)88-54(38(75)31(45)68)96-46-26(13-63)92-58(42(79)35(46)72)101-51-30(19-103-17-22(53(84)85)10-23(67)5-7-87-9-8-86-6-4-20(2)66)94-60(44(81)37(51)74)99-49-28(15-65)90-56(40(77)33(49)70)97-47-25(12-62)91-57(100-50)41(78)34(47)71;1-21-12-11-13-22(2)31(39)24(4)32(40)33(6,7)28(41-30(38)14-9-8-10-17-34)19-29(37)36-27(16-15-21)23(3)18-26-20-42-25(5)35-26/h21-22,24-51,54-65,68-81H,3-19H2,1-2H3,(H,82,83)(H,84,85);11,13,15,18,20,22,24,27-28,31,39H,8-10,12,14,16-17,19,34H2,1-7H3,(H,36,37)/b;13-11-,21-15-,23-18+/t21?,22?,24?,25?,26?,27?,28?,29?,30?,31-,32-,33-,34-,35-,36-,37-,38?,39?,40?,41?,42?,43?,44?,45-,46-,47-,48-,49-,50-,51-,54-,55-,56-,57-,58-,59-,60-;22-,24+,27-,28-,31-/m10/s1 |
| InChIKey | AENGZUVIOVNECD-ISSWUSBFSA-N |
| XLogP | -5.89 |
| TPSA | 772.40 Ų |
| H-Bond Donors | 24 |
| H-Bond Acceptors | 49 |
| Rotatable Bonds | 35 |
| Heavy Atoms | 145 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 2141.39 |
| LogP ≤ 5 | -5.89 |
| H-Bond Donors ≤ 5 | 24 |
| H-Bond Acceptors ≤ 10 | 49 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'isolated_alkene', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 157089729 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.